Jeanne Ernst, APRN
Adult Health · Wolfeboro, NHNPI 1861416182
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 31.8% of the total. Reporting peaked in 2023 at $643 and has fallen 73.7% since, to $169 in 2025. Among adult health clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$522
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$255
- Lundbeck LLC$155
- Scilex Pharmaceuticals Inc.$140
- Valinor Pharma, LLC$97
- Teva Pharmaceuticals USA, Inc.$92
- plus $382 from 11 others
What the payments were for
- Food & beverage$1,643100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $522 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $255 |
| Lundbeck LLC | 8 | $155 |
| Scilex Pharmaceuticals Inc. | 8 | $140 |
| Valinor Pharma, LLC | 5 | $97 |
| Teva Pharmaceuticals USA, Inc. | 5 | $92 |
| Pfizer | 4 | $86 |
| Lilly USA, LLC | 3 | $57 |
| Amgen | 3 | $44 |
| Biodelivery Sciences International, Inc. | 3 | $42 |
| Collegium Pharmaceutical, Inc. | 2 | $36 |
| GRT US Holding, Inc. | 2 | $35 |
| Boston Scientific | 1 | $24 |
| Gilead | 1 | $16 |
| Braeburn Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $12 |
How this compares
$1,643 in reported general payments places this provider in the 90th percentile of 81 adult health providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucyntaTapentadol Hcl | 25 | $41,804 |
| OxycontinOxycodone Hcl | 48 | $31,179 |
| Xtampza ErOxycodone Myristate | 24 | $20,276 |
| BelbucaBuprenorphine Hcl | 18 | $14,367 |
| Oxycodone Hcl | 340 | $10,487 |
| Buprenorphine | 16 | $5,196 |
| Morphine Sulfate ErMorphine Sulfate | 93 | $2,934 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 55 | $2,759 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $2,249 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 55 | $2,210 |
| Fentanyl | 19 | $2,060 |
| Gabapentin | 124 | $1,876 |
| Buprenorphine Hcl | 53 | $1,622 |
| Pregabalin | 45 | $1,527 |
| Cyclobenzaprine Hcl | 76 | $1,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Belbuca | $36 | $76,44667 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Buprenorphine Hcl, Morphine Sulfate | $12 | $9,729108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 81 adult health providers in New Hampshire.
Other adult health in Wolfeboro
- Carlene Vasquez-BrownLaconia$10K
- Lisa Kennedy-SheldonPortsmouth$7K
- Richard LapageConcord$5K
- Patty DumontManchester$3K
- Jane TallentDover$2K
- Cara Jean DonagheyNashua$2K
- Elizabeth DuffyHudson$2K
- Jill BickfordPortsmouth$1K
- Margaret AbbottConcord$1K
- Elaine BrynNewington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.